Two separate dose-dependent effects of paroxetine: Mydriasis and inhibition of tramadol's O-demethylation via CYP2D6

European Journal of Clinical Pharmacology

Volumn 66, Issue 7, 2010, Pages 655-660

  Nielsen, Anette Green ^a   Pedersen, Rasmus Steen ^a   Noehr Jensen, Lene ^a   Damkier, Per ^b   Brosen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CYP2D6; Interaction; Metabolic ratios; Paroxetine; Pupillometry; Tramadol

Indexed keywords

CYTOCHROME P450 2D6; O NORTRAMADOL; PAROXETIN; PAROXETINE; PLACEBO; TRAMADOL; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6 INHIBITOR; NARCOTIC ANALGESIC AGENT; O-DEMETHYLTRAMADOL;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMETHYLATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG METABOLISM; DRUG URINE LEVEL; ENANTIOSELECTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INHIBITION KINETICS; MALE; MYDRIASIS; NORMAL HUMAN; PRIORITY JOURNAL; PUPIL REFLEX; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG INTERACTION; PUPIL; URINE;

ADULT; ANALGESICS, OPIOID; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; PAROXETINE; PUPIL; TRAMADOL; CYTOCHROME P-450 CYP2D6 INHIBITORS;

EID: 77955562826     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0803-8     Document Type: Article

References (35)

1. Bair MJ, Robinson RL, Katon W, Kroenke K (2003) Depression and pain comorbidity. Arch Intern Med 163:243-245
2. Trescot AM, Datta S, Lee M, Hansen H (2008) Opioid pharmacology. Pain Physician 11:133-153, Opioid Special Issue
3. Paar WD, Frankus P, Dengler HJ (1992) The metabolism of tramadol by human liver microsomes. Clin Investig 70:708-710
4. Paar WD, Poche S, Gerloff J, Dengler HJ (1997) Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 53:235-239
5. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH (1996) The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 60:636-644
6. Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K (2005) Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 77:312-323
7. Pedersen RS, Damkier P, Brosen K (2006) Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol 62:513-521
8. Halling J, Weihe P, Brosen K (2008) CYP2D6 polymorphism in relation to tramadol metabolism: a study of Faroese patients. Ther Drug Monit 30:271-275
9. Raffa RB, Friederichs E, Reimann W, Shank RP, Codd EE, Vaught JL (1992) Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an atypical opioid analgesic. J Pharmacol Exp Ther 260:275-285
10. Lai J, Ma SW, Porreca F, Raffa RB (1996) Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in HN9.10 neuroblastoma cells. Eur J Pharmacol 316:369-372
11. Bamingbade TA, Davidson C, Langford RM, Stamford JA (1997) Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth 79:352-356
12. Halfpenny DM, Callado LF, Hopwood SE, Bamigbade TA, Langford RM, Stamford JA (1999) Effects of tramadol stereoisomers on norepinephrine efflux and uptake in the rat locus coeruleus measured by real time voltammetry. Br J Anaesth 83:909-915
13. Zanger UM, Turpeinen M, Klein K, Schwab M (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093-1108
14. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorfisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526
15. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom J 5:6-13
16. Sindrup SH, Brosen K, Gram LF (1992) Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:288-295
17. Sindrup SH, Brosen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TC et al (1992) The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:278-287
18. Brosen K, Gram LF, Kragh-Sørensen P (1991) Extremely slow metabolism of amitriptyline but normal metabolism of imipramine dnd Desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Ther Drug Monit 13:177-182
19. Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF (1993) Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 44:349-355
20. Skjelbo E, Brosen K (1992) Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34:256-261
21. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262-265
22. Bertelsen KM, Venkatakrishnan K, Moltke L, Obach RS, Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Disp 31:289-293
23. Venkatakrishnan K, Obach RS (2005) In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Disp 33:845-852
24. Fliegert F, Kurth B, Göhler (2005) The effects of tramadol on static and dynamic pupillometry in healthy subjects-the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Eur J Clin Pharmacol 61:257-266
25. Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, Nielsen F, Brosen K, Sindrup SH (2009) The hypoalgesic effect of oxycodone in human experimental painmodels in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol Toxicol 104:335-344
26. Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Brosen K (2009) Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. Clin Pharmacol Ther 86:626-633
27. Pedersen RS, Brosen K, Nielsen F (2003) Enantioselective HPLC method for quantitative determination of tramadol and Odesmethyltramadol in plasma and urine: application to clinical studies. Chromatographia 57:279-285
28. Pedersen RS, Damkier P, Brosen K (2005) Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther 77:458-467
29. Johnson AM (1989) An overview of the animal pharmacology of paroxetine. Acta Psychia Scan 80:14-20
30. Danish Medicines Agency (2009) Product resume for Seroxat®.http:// www.produktresume.dk. Accessed June 18, 2009
31. Larson M, Folstein S (2000) Selective serotonin reuptake inhibitorinduced mydriasis. J Am Acad Child Adolesc Psych 39:138-139
32. Bitsios P, Szabadi E, Brandshaw CM (1999) Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology 143:286-292 (Pubitemid 29204983)
33. Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Nielsen F, Brosen K (2009) Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonegic biomarker. Eur J Clin Pharmacol 65:887-894
34. Jeppesen U, Gram LF, Vistisen K, Loft H, Poulsen HE, Brosen K (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51:73-78
35. Fuur U, Jetter A, Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and simultaneous use in the "cocktail approach". Clin Pharmacol Ther 81:270-283